[Prevention of mycotic infections in oncology patients with regard to the toxicity of antimycotic agents].
Profound and prolonged neutropenia following chemotherapy is a major risk factor for systemic fungal infections. It is still unclear how effective the various measures that are currently being used are in preventing serious fungal infection. Although a number of studies have been published on antifungal prophylaxis in neutropenic patients, there are a lot of conflicting data. At the present time, it seems that antifungal prophylaxis is more a matter of faith rather than science. The prophylactic use of fluconazole or itraconazole may reduce the incidence of systemic fungal infections in high-risk patient groups, mainly in patients with haematological malignancies. The antifungals currently used for prophylaxis in immunocompromised patients, and the toxicity of the antifungals are reviewed.
Doubek
M
M
Interní hematoonkologická klinika Fakultní nemocnice Brno, pracovistĕ Bohunice.
Mayer
J
J
Horký
D
D
Doubek
J
J
Rácil
Z
Z
Vorlícek
J
J
D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000517:prevention & control*; D009369:Neoplasms / Q000382:microbiology*; D009894:Opportunistic Infections / Q000517:prevention & control*
D000935:Antifungal Agents